Biote 's (BTMD) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Biote Corp   (NASDAQ: BTMD)
 



  Biote Corp Outlook

On March 12 2024 the Biote Corp provided following guidance

Biote Corp announced their financial results for the fourth quarter and full year 2023, with a focus on preventive health care and personalized hormone optimization. The company reported revenue of $45.7 million for the fourth quarter, representing a 2.7% increase compared to the previous year. This revenue figure was in line with the company's pre-released financial guidance.

Throughout the year, Biote Corp has been a leader in providing solutions for preventive health care through personalized hormone optimization and therapeutic wellness. The company's focus on delivering personalized care has led to a steady increase in revenue, reflecting the growing demand for personalized health solutions.

Biote Corp's financial performance in 2023 showcases their commitment to delivering innovative health solutions and meeting the needs of their customers. The company's strong revenue growth in the fourth quarter is a testament to their success in the preventive health care industry.

Overall, Biote Corp's financial results for the fourth quarter and full year 2023 highlight their continued growth and success in providing personalized health solutions to their customers. The company's dedication to preventive health care and personalized hormone optimization positions them as a leader in the industry.

On January 17 2024 the Biote Corp provided following guidance

64 million, respectively.

For the year 2023, Biote Corp. is anticipating slightly lower revenue and Adjusted EBITDA compared to previous expectations. The company initially projected revenue and Adjusted EBITDA to fall within the range of $190-$200 million and $56-$64 million, respectively.

This preliminary announcement suggests that Biote Corp.'s financial performance for 2023 may not meet the lower end of the previously indicated ranges. However, specific figures detailing the revised estimates have not been provided.

Biote Corp. is a prominent provider of personalized hormone optimization and therapeutic wellness solutions in the field of preventive healthcare. The company's primary focus is on the delivery of individualized services to optimize customer health and well-being.

Moving forward into 2024, Biote Corp. intends to establish its initial guidance for the year. However, no specific details regarding revenue or Adjusted EBITDA targets have been disclosed at this time.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.